Alzheon
MA - FraminghamBiotechnology
Focus: Alzheon is a small-molecule focused biotech company targeting Alzheimer's disease, currently advancing a Phase 3 program (ALZ-801) for early AD. The company is public and based in Framingham, MA, with a specialized focus on neurology.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Alzheon
AI assessmentNot HiringNo open roles listed right now. Follow Alzheon to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ALZ-801
Early Alzheimer's DiseaseClinical Trials (5)
NCT06304883Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
Phase 3Help build intelligence for Alzheon
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.